Cerner Enviza, an independent research agency, is collaborating with a sponsoring pharmaceutical company, with the assistance of UK melanoma charities and Global Patients, to conduct an online research to collect the opinion of patients with stage 2, 3 or 4 melanoma about the potential benefits and risks related to melanoma treatments.
The data from this research aims provide the medical community with a better understanding of what treatment characteristics are most important to patients. If you would like to participate please contact Global Patients (the agency in charge of recruitment) directly stating your wish to participate at firstname.lastname@example.org.
Global Patients will contact you to answer a few preliminary questions to check your eligibility for the research. If you are eligible, you will receive a link to the online research which will take approximately 30 minutes to complete and as a token of appreciation you will receive £50.
Your participation will help inform the understanding of the preferences of patients affected by melanoma. The overall aggregated findings of the research may be published in scientific journals, but any identifiable information will be removed. Please engage with Melanoma Focus if you want to receive the published results by contacting email@example.com
This study is now closed– we appreciate your participation.